The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Genomic testing of lung cancer via Genomic Laboratory Hubs
Genomic Laboratory Hubs (GLHs) have been set up by the NHS to enhance and standardize genomic testing throughout the country. Neal Navani, MA, MRCP, MSc, PhD, Care Quality Improvement Department, Royal College of Physicians, London, UK, discusses the current state of GLHs and what needs to be done to advance them. Lung cancer screening has currently not been implemented in every GLH due to logistical barriers and COVID-19, and increased funding and capacity will enhance the current capabilities of molecular testing. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Dr Navani has received honoraria for speaking, advisory boards or travel support from Amgen, Aidence, Astra Zeneca, Lilly, Takeda, Janssen, Merck, MSD, Pfizer, Oncimmune, PeerVoice, OncLive, Bristol-Meyers-Squibb and Olympus, as well as educational grants from Olympus, Cook Medical, Hitachi and Pentax.
